Pangaea Oncology S.A. (PANG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has a cash flow conversion efficiency ratio of -0.060x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.26 Million ≈ $-1.48 Million USD) by net assets (€21.14 Million ≈ $24.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Pangaea Oncology S.A. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Pangaea Oncology S.A. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See Pangaea Oncology S.A. book value and equity for net asset value and shareholders' equity analysis.
Pangaea Oncology S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pangaea Oncology S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DocGo Inc
NASDAQ:DCGO
|
-0.083x |
|
Rumble Resources Ltd
AU:RTR
|
-0.030x |
|
PTL Enterprises Limited
NSE:PTL
|
0.025x |
|
TegoScience Inc
KQ:191420
|
-0.025x |
|
Minna Padi Investama Tbk
JK:PADI
|
0.007x |
|
RYTHM, Inc.
NASDAQ:RYM
|
0.029x |
|
Theragen Etex Co.Ltd
KQ:066700
|
0.024x |
|
Sonel S.A.
WAR:SON
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Pangaea Oncology S.A. from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see PANG stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €22.84 Million ≈ $26.70 Million |
€-4.57 Million ≈ $-5.34 Million |
-0.200x | -56.82% |
| 2023-12-31 | €18.81 Million ≈ $21.99 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.127x | +19.97% |
| 2022-12-31 | €23.08 Million ≈ $26.98 Million |
€-3.68 Million ≈ $-4.30 Million |
-0.159x | +10.27% |
| 2021-12-31 | €14.09 Million ≈ $16.47 Million |
€-2.50 Million ≈ $-2.92 Million |
-0.178x | +20.60% |
| 2020-12-31 | €8.57 Million ≈ $10.01 Million |
€-1.92 Million ≈ $-2.24 Million |
-0.224x | +22.45% |
| 2019-12-31 | €8.31 Million ≈ $9.72 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.288x | -14.68% |
| 2018-12-31 | €8.62 Million ≈ $10.07 Million |
€-2.17 Million ≈ $-2.53 Million |
-0.251x | +80.42% |
| 2017-12-31 | €5.05 Million ≈ $5.90 Million |
€-6.48 Million ≈ $-7.58 Million |
-1.284x | -336.22% |
| 2016-12-31 | €6.05 Million ≈ $7.07 Million |
€-1.78 Million ≈ $-2.08 Million |
-0.294x | +86.59% |
| 2015-12-31 | €1.05 Million ≈ $1.23 Million |
€-2.31 Million ≈ $-2.70 Million |
-2.194x | -88.79% |
| 2014-12-31 | €1.63 Million ≈ $1.90 Million |
€-1.89 Million ≈ $-2.21 Million |
-1.162x | -221.80% |
| 2013-12-31 | €1.83 Million ≈ $2.14 Million |
€-659.69K ≈ $-771.25K |
-0.361x | -- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more